

Research Journal of Pharmaceutical, Biological and Chemical Sciences

Sterols from *Trametes versicolor*.

Melissa S Borlagdan^{1, 2}, Ma Ellenita G De Castro³, Ian A van Altena⁴ and Consolacion Y Ragasa^{1, 5*}

¹Chemistry Department, De La Salle University, 2401 Taft Avenue, Manila 1004, Philippines,

²Department of Science and Technology-Food and Nutrition Research Institute, Bicutan, Taguig, Metro Manila, Philippines,

³Biology Department, De La Salle University, 2401 Taft Avenue, Manila 1004, Philippines,

⁴School of Environmental and Life Sciences, Faculty of Science and Information Technology, Chemistry, The University of Newcastle-Australia, Callaghan, NSW, 2308, Australia,

⁵Chemistry Department, De La Salle University Science & Technology Complex Leandro V. Locsin Campus, Biñan City, Laguna 4024, Philippines

ABSTRACT

Chemical investigation of the dichloromethane extract of the fruiting bodies of *Trametes versicolor* yielded ergosterol peroxide (**1**) and a mixture of stllasterol (**2**) and ergosterol (**3**) in a 3.6:1 ratio. The structures of **1-3** were identified by comparison of their NMR data with literature data.

Keywords: *Trametes versicolor*, Polyporaceae, ergosterol peroxide, stllasterol, ergosterol

*Corresponding author

INTRODUCTION

Trametes versicolor also known as Turkey tail mushroom grows on decaying hardwood or at the base of trees [1]. It is known to possess diverse biological activities including immune-enhancing [2], antitumor [3], and antiviral [4] activities. A protein-bound polysaccharide, polysaccharide-K (PSK or Krestin), extracted from *T. versicolor*, is used in cancer treatment [5, 6]. The anticancer effects and mechanisms of PSK for cancer immunotherapy has been reported [7]. The ethyl acetate and the ethanol extracts of *T. versicolor* exhibited anti-leishmanial activity with IC_{50} values of $101.8 \pm 4.2 \mu\text{g/mL}$ and $97.4 \pm 2.0 \mu\text{g/mL}$, respectively [8]. The hexane extract of the fruiting bodies of *T. versicolor* yielded ergosterol peroxide, stellersterol, and trametenolic acid [9]. Another study reported the isolation of 4-isobutoxyphenyl palmitate, cerebroside, 3β -linoleoyloxyergosta-7,22-diene, 3β -linoleoyloxyergosta-7-ene, betulinic acid, ergosterol, ergosterol peroxide, trilinolein, ergosta-7, 22-dien- 3β -ol, and betulin [10].

This study is part of our research on the chemical constituents of mushrooms found and cultivated in the Philippines. We earlier reported the isolation of ergosterol peroxide from *Auricularia auricula-judae* [11]; ergosterol, brassicasterol, trilinolein and linoleic acid from *Agaricus bisporus* [12]; ergosterol and trilinolein from *Lentinus edodes* [13]; ergosterol, triacyl glycerols and fatty acid methyl esters from *Pleurotus djamor* [14]; ergosterol and triacylglycerols from *Phellinus gilvus* [15]; and ergosterol, ergosterol peroxide, cerevisterol, palmitic acid, stearic acid, linoleic acid, oleic acid and dilinolenoyloleoylglycerol from *Pleurotus florida* [16].

We report herein the isolation of ergosterol peroxide (**1**) and a mixture of stellersterol (**2**) and ergosterol (**3**) from *T. versicolor*. The structures of **1-3** are presented in Fig. 1




Fig 1: Ergosterol peroxide (**1**) and a mixture of stellersterol (**2**) and ergosterol (**3**) from *T. versicolor*.

MATERIALS AND METHODS

General Experimental Procedure

^1H NMR spectra were recorded in CDCl_3 on a Bruker Ascend 400 in CDCl_3 at 400 MHz. Column chromatography was performed with silica gel 60 (70-230 mesh, Merck). Thin layer chromatography was performed with plastic backed plates coated with silica gel F₂₅₄ (Merck) and the plates were visualized by spraying with vanillin/ H_2SO_4 solution followed by warming. All solvents used were of analytical grade.

Sample Collection

The sample was collected from Zamboanga, Philippines in January, 2016. It was authenticated as *Trametes versicolor* by one of the authors (MEDC) based on the available literature.

General Isolation Procedure

A glass column 18 inches in height and 1 inch internal diameter was used for the fractionation of the crude extracts. Eleven 20 mL fractions were collected. A glass column 12 inches in height and 0.5 inch internal diameter was used for the rechromatography of fractions from the crude extracts. 2 mL fractions were collected. Fractions with spots of the same R_f values were combined and rechromatographed in appropriate solvent systems until TLC pure isolates were obtained. Rechromatography and final purifications were conducted using Pasteur pipettes as columns. 1 mL fractions were collected.

Isolation of Chemical Constituents

The air-dried *A. scholaris* leaves (25.3 g) were ground in a blender, soaked in CH_2Cl_2 for 3 days and then filtered. The solvent was evaporated under vacuum to afford a crude extract (0.5 g) which was chromatographed using increasing proportions of acetone in CH_2Cl_2 in 10% increments by volume. The 40% acetone in CH_2Cl_2 fraction was rechromatographed (2 \times) using 15% EtOAc in petroleum ether to afford a mixture of **2** and **3** (3 mg) after washing with petroleum ether. The 50% acetone in CH_2Cl_2 fraction was rechromatographed using 15% EtOAc in petroleum ether. Fractions from this column were rechromatographed using 20% EtOAc in petroleum ether to yield **1** (2 mg) after washing with petroleum ether.

Ergosterol peroxide (1): $^1\text{H-NMR}$ (400 MHz, CDCl_3): δ 6.49 (d, $J=8.4$, H-6), 6.22 (d, $J=8.4$, H-7), 5.12 (dd, $J=8$, 15.2 Hz, H-20), 5.22 (dd, $J=7.2$, 15.2 Hz, H-23), 3.95 (m, H-3), 0.80 (s, Me-18), 0.86 (s, Me-19), 0.97 (d, $J=8$ Hz, Me-21), 0.79 (3H, d, $J=6.8$ Hz, H-26), 0.81 (3H, d, $J=6.4$ Hz, H-27), 0.88 (3H, d, $J=6.8$ Hz, H-28).

Stellasterol (2): $^1\text{H-NMR}$ (400 MHz, CDCl_3): (δ , ppm) 0.52 (s, H_3 -18), 0.80 (d, $J=6.4$ Hz, H_3 -26), 0.82 (d, $J=6.4$ Hz, H_3 -27), 0.78 (s, H_3 -19), 0.90 (d, $J=6.8$ Hz, H_3 -28), 0.99 (d, $J=6.4$ Hz, H_3 -21), 3.6 (m, H-3), 5.20 (t, $J=6.8$ Hz, H-7), 5.15 (m, 2H, H-22, H-23); $^{13}\text{C-NMR}$ (100 MHz, CDCl_3): (δ , ppm): 37.98 (C-1), 31.47 (C-2), 71.06 (C-3), 37.13 (C-4), 49.44 (C-5), 29.69 (C-6), 117.45 (C-7), 139.56 (C-8), 40.47 (C-9), 34.21 (C-10), 21.53 (C-11), 39.44 (C-12), 43.28 (C-13), 55.10 (C-14), 22.92 (C-15), 28.09 (C-16), 55.95 (C-17), 12.08 (C-18), 13.03 (C-19), 40.25 (C-20), 21.10 (C-21), 131.87 (C-22), 135.66 (C-23), 42.80 (C-24), 33.08 (C-25), 19.63 (C-26), 19.94 (C-27), 17.58 (C-28).

Ergosterol (3): $^1\text{H-NMR}$ (400 MHz, CDCl_3): δ 5.57 (dd, $J=2.8$, 5.6 Hz, H-6), 5.38 (dd, $J=2.8$, 5.6 Hz, H-8), 5.22 (m, H-23), 5.15 (m, H-22), 3.63 (m, H-3), 1.01 (d, $J=8.4$ Hz, H-21), 0.93 (s, H-19), 0.91 (d, $J=6.0$ Hz, H-28), 0.85 (d, $J=6$ Hz, H-26), 0.82 (d, $J=6$ Hz, H-27), 0.61 (s, H-18).

RESULTS AND DISCUSSION

Silica gel chromatography of the dichloromethane extract of *Trametes versicolor* yielded ergosterol peroxide (**1**) and a mixture of stellasterol (**2**) and ergosterol (**3**). The NMR spectra of **1** are in accordance with data reported in the literature for ergosterol peroxide [16]; **2** for stellasterol [9]; and **3** for ergosterol [16]. The 3.6:1 ratio of stellasterol (**2**) and ergosterol (**3**) was deduced from integrations and intensities of the resonances for methyl protons at δ 0.52 (s, H_3 -18) for **2** and δ 0.61 (s, H_3 -18) for **3**.

Although bioassays were not conducted on the isolated compounds, there were previous studies that reported on their biological activities.

A number of studies have been conducted on the biological activities of ergosterol peroxide (**1**). Compound **1** isolated from *Pleurotus ostreatus* (Jacq.) P. Kumm. f. sp. florida showed strongly panocidal activity on the intracellular form of *T. cruzi* with an IC_{50} of 6.74 $\mu\text{g}/\text{mL}$ [17]. Sterol **1** from an edible mushroom suppresses inflammatory response in RAW 264.7 macrophages and growth of HT29 colon adenocarcinoma cells [18]. In addition, **1** was shown to exhibit anti-tumor activity in multiple myeloma U266 cells, Walker carcinosarcoma, human mammary adenocarcinoma, human gastric tumor (SNU-1), human hepatoma (SUN-354), human colorectal tumor (SUN-C4), and murine sarcoma-180 cell lines [19]. The IC_{50} value of **1** based on the

cell viability of Hep3B was 16.7 µg/mL [20]. It exhibited an inhibitory effect on androgen-sensitive (LNCaP) and androgen-insensitive (DU-145) human prostate cancer cells at µM concentrations [21] and suppressed cell growth and STAT1 mediated inflammatory responses in HT29 cells [22]. It inhibited the growth and induced apoptosis of HL60 human leukaemia cells at a concentration of 25 µM, inhibited TPA induced inflammation and tumor promotion in mice and suppressed proliferation of mouse and human lymphocytes stimulated with mitogens [23]. It displayed potent activity against the cancer cell lines MDA-MB435, HCT-8 and SF-295 [24] and induced death of MIR-378 cell [25]. It exhibited significant inhibitory activities against leishmaniasis, tuberculosis, *Mycobacterium tuberculosis* H37Rv and *M. avium* [26], and inhibited the hemolytic activity of human serum against erythrocytes [27]. Sterol **1** significantly blocked MyD88 and VCAM-1 expression, and cytokine (IL-1β, IL-6 and TNF-α) production in LPS-stimulated cells and effectively inhibited NF-κB activation which indicated that it may play an important role in the immunomodulatory activity of *Grifola frondosa* [28]. It possessed marked activity against PGE₂ release with an IC₅₀ value of 28.7 µM. The mechanism in transcriptional level of **1** was found to down-regulate mRNA expressions of iNOS and COX-2 in dose-dependent manners [29]. Furthermore, **1** suppressed LPS-induced DNA binding activity of NF-κB and C/EBPβ and inhibited the phosphorylation of p38, JNK and ERK MAPKs. It down-regulated the expression of low-density lipoprotein receptor (LDLR) regulated by C/EBP, and HMG-CoA reductase (HMGCR) in RAW264.7 cells. Moreover, **2** induced the expression of oxidative stress-inducible genes, and the cyclin-dependent kinase inhibitor CDKN1A, and suppressed STAT1 and interferon-inducible genes [30].

Stellasterol (**2**) showed antibiotic activity against gram positive bacteria [31]. Another study reported that cell cycle arrest against the human cancer cell lines, MCF-7 and SH-SY5Y was exhibited by stellasterol [32]. Furthermore, **2** exhibited anti-inflammatory activity against iNOS, CHOP and IκB-α expression [33].

A study reported that ergosterol (**3**) provides significant protection against the promotion of bladder tumor induced by many types of promoters in the environment [34]. Oral administration of **3** (400 and 800 mg/kg) for 20 days to sarcoma 180 bearing mice significantly reduced tumor growth [35]. Furthermore, **3** showed antifibrotic effect *in vivo* and *in vitro* [36].

REFERENCES

- [1] *Trametes versicolor*: The Colorful Turkey Tail Mushroom. Downloaded from <http://www.mushroom-appreciation.com/trametes-versicolor.html#sthash.aLC06QBE.dpuf> on December 25, 2016.
- [2] Li F, Wen H, Zhang Y, Aa M, Liu X, Sci China Life Sci 2011; 54: 379–85.
- [3] Standish LJ, Wenner CA, Sweet ES, Bridge C, Nelson A, Martzen M, Novack J, Torkelson C. J Soc Integr Oncol 2008; 6: 122–128.
- [4] Teplyakova TV, Psurtseva NV, Kosogova TA, Mazurkova NA, Khanin VA, Vlasenko VA. Int J Med Mushrooms 2012; 14: 37–45.
- [5] Fisher M, Yang LX. Anticancer Res 2002; 22: 1737–1754.
- [6] Tsukagoshi S, Hashimoto Y, Fujii G, Kobayashi H, Nomoto K, Orita K. Cancer Treat Rev 1984; 11: 131–55.
- [7] Fisher MY, Yang LX. Anticancer Res 2002; 22(3): 1737–1754.
- [8] Leliebre-Lara V, Garcia M, Nogueiras C, Monzote L. Emir J Food Agric 2015; 27(7): 592–595.
- [9] Leliebre-Lara V, Monzote Fidalgo L, Pferschy-Wenzig EM, Kunert O, Nogueiras Lima C, Bauer R. Molecules 2016; 21: 1045.
- [10] Habibi E, Sadat-Ebrahimi SE, Mousazadeh SA, Amanzadeh Y. Int J Med Mushrooms 2015; 17(3): 255–65.
- [11] Ragasa CY, Tan MCS, De Castro MEG, Shen C-C. Der Pharma Chemica 2016; 8(16): 168–171.
- [12] Ragasa CY, Reyes JMA, Tan MCS, Brkljača R, Urban S. Int J Pharm Clin Res 2016; 8(10): 1451–1453.
- [13] Resurreccion NGU, Shen C-C, Ragasa CY. Der Pharmacia Lettre 2016; 8(4): 117–120.
- [14] Ragasa CY, Tan MCS, Ting J, Reyes RG, Brkljača R, Urban S. Der Pharma Chemica 2016; 8(2): 343–346.
- [15] Ragasa CY, Tan MCS, De Castro E, van Altena IA. Der Pharma Chemica 2016; 8(19): 222–225.
- [16] Ragasa CY, Ebajo Jr. VD, Reyes RG, Brkljača R, Urban S. Der Pharma Chemica 2015; 7(10): 331–336.
- [17] A. Ramos-Ligonio, A. López-Monteon, A. Trigos. Phytother Res 2012; 26(6), 938–43.
- [18] M. Kobori, M. Yoshida, M. Ohnishi-Kameyama, H. Shinmoto. Brit J Pharmacol 2007; 150(2): 209–219.
- [19] Y. H. Rhee, S. J. Jeong, H. J. Lee, W. Koh. BMC Cancer 2012; 12: 28.
- [20] T. Takei, M. Yoshida, M. Ohnishi-Kameyama, M. Kobori. Biosci Biotechnol Biochem 2005; 69, 212–215.
- [21] Y. K. Chen, Y. H. Kuo, Y. Chiang, J. M. Lo, L. Y. Sheen. J. Agric. Food Chem 2009, 57: 5713–5719.
- [22] A. Russo, V. Cardile, M. Piovano, S. Caggia, C. L. Espinoza. Chem Biol Interact 2010; 184: 352–358.
- [23] F. Leon, L. Brouard, F. Torres, J. Quintana, A. Rivera. Chem Biodivers 2008; 5: 120–125.

- [24] X. Liu, C. Y. Wang, C. L. Shao, X. Y. Wei, B. G. Wang. *Biochem Syst Ecol* 2009; 37: 127-129.
- [25] Q. P. Wu, Y. Z. Xie, Z. Deng, X. M. Li, W. Yang. *PLoS One* 2012; 7: e44579.
- [26] E. Correa, D. Cardona, W. Quiaones, F. Torres, A. E. Franco. *Phytother Res* 2006; 20: 497-499.
- [27] H. W. Seo, T. M. Hung, M. Na, H. J. Jung, J. C. Kim. *Arch Pharm Res* 2009; 32: 1573-1579.
- [28] S. J. Wu, T. M. Lu, M. N. Lai, L. T. Ng. *Am J Chin Med* 2013; 41: 131-144.
- [29] S. Tewtrakul, P. Tansakul, C. Daengrot, C. Ponglimanont, C. Karalai, *Phytomed* 2010; 17: 851- 855.
- [30] J. K. Rugutt, K. J. Rugutt, *Nat. Prod Res* 2012; 26: 1004-1011.
- [31] D. M. Vazirian, M. A. Faramarzi, S. E. Ebrahimi, H. R. Esfahani, N. Samadi, S. A. Hosseini, A. Asghari, A. Manayi, A. Mousazadeh, M. R. Asef, E. Habibi, Y. Amazadeh. *Int J Med Mushrooms* 2014;16(1):77-84.
- [32] D. M. Pereira, G. Correia-da-Silva, P. Valentão, N. Teixeira, P. B. Andrade. *Mar Drugs* 2014; 12(1): 54–68..
- [33] D. M. Pereira, G. Correia-da-Silva, P. Valentão, N. Teixeira, P. B. Andrade. *PLoS ONE* 2014; 9(2): e88341.
- [34] Y. Yazawa, M. Yokota, K. Sugiyama, *Biol Pharm Bull* 2000; 23(11): 1298–302.
- [35] T. Takaku, Y. Kimura, H. Okuda, *J Nutr* 2001; 131: 1409-1413.
- [36] P. Yuan, T. Yanyan,,W. Qinglan, L. Shen, T. Yang, Z. Liu, C. Liu. *Evid Based Complement Alternat Med* 2014; article ID 537234, 12 pages
-